Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 261 participants.

Also called NCT01538875

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 261 participants (enrolled count) (from the registry)
Sponsor
Saint Thomas Hospital, Panama (from the registry)
Registry
  • NCT NCT01538875
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Panama (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01538875. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy
Condition
Hypertension, Pregnancy Induced
Intervention (Drug)
Hydralazine
Intervention (Drug)
Labetalol
Lead sponsor
Saint Thomas Hospital, Panama (class: other)

Record details

Record id
cardio:ct-nct01538875
Content hash
9e8225e172e411ca087fde9fa6d2de4596661eeea1be32f5fde7ee77e2eb2fb5